Pharmacyclics Inc.

Pharmacyclics, Inc. is a pharmaceutical company developing energy-potentiating drugs to improve radiation therapy and chemotherapy of cancer, and to enable or improve the photodynamic therapy of certain cancers and atherosclerotic cardiovascular disease. The Company's products are small ring-shaped molecules, called texaphyrins, which are patented agents derived from Pharmacyclics' versatile technology platform for designing and synthesizing energy-potentiating drugs. These texaphyrins localize in cancer cells and atherosclerotic plaque, where they can be activated by forms of energy, including X-ray, chemical and light, to eliminate diseased tissue. The Company's lead texaphyrin-based product candidates are XCYTRINŽ (motexafin gadolinium) radiation sensitizer, a gadolinium texaphyrin drug being developed for potential use in radiation therapy; LUTRINŽ (motexafin lutetium) photosensitizer, a lutetium texaphyrin molecule for potential use in the photodynamic therapy (PDT) of cancer; ANTRINŽ (motexafin lutetium) photosensitizer, a lutetium texaphyrin molecule for potential use in the photoangioplasty of atherosclerosis; and OPTRINTM (motexafin lutetium) photosensitizer, a lutetium texaphyrin molecule for potential use in the photodynamic therapy of ophthalmic diseases, such as age-related macular degeneration; and a gadolinium texaphyrin molecule for potential use as a chemosensitizer. In September 1998, a multicenter Phase III clinical trial was initiated of XCYTRINŽ radiation sensitizer to improve the efficacy and safety of radiation therapy of brain metastases resulting from a variety of cancers, including those of the lung and breast.

Activity:

- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: